Abstract Abstract 603 Background: Imatinib treatment significantly improves survival in
patients (pts) with CML. We previously demonstrated that Imatinib could be safely …

Abstract Abstract 3754 Background Imatinib (IM) has dramatically improved the prognosis of
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …

Background Monitoring response to TKI therapy is one of the key management strategies of
chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is …

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …

Abstract 2790 The approval of second-generation tyrosine kinase inhibitors (TKIs) for the
first line treatment of Chronic Myeloid Leukemia (CML) has generated a need for early …

Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …

Tyrosine kinase inhibitors (TKI) have dramatically changed the management and the
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …

Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …

Introduction: Early prediction of outcome using response-related predictive landmarks has
become a major paradigm in the clinical management of chronic myeloid leukemia (CML) …